It could be worse. In fact it is reasonably promising. Tali will...

It could be worse. In fact it is reasonably promising. Tali will continue to own the IP and the products, and will ride off the sales by Genuis (who will effectively cover all operating and support and sales costs).

Note also, Genuis will "...act as exclusive distributor of TALi’s products in the education sector and non‐exclusively across the healthcare sector..." which suggests another potential deal in the pipeline for sales & distribution in the healthcare segment if demand exists/occurs. Hopefully Mary-Beth can bring her Cochlear experience and network to this task to earn her consulting fee/success fee keep.

Tali increasingly looking like a shell co now rather than a medtech developer. They will have to embark on something else, surely, to prove they are continuing their core business activity and retain their ASX listing without being asked to recomply with chapters 1 & 2?